Merck and Moderna just dropped explosive early results from a late-stage melanoma trial: their personalized mRNA cancer vaccine, paired with Keytruda, significantly delayed cancer recurrence and reduced spread—with minimal side effects. Doctors are thrilled, calling it a “clinically meaningful” leap over standard treatment. The therapy, tailored to each patient’s tumor mutations, could soon expand to lung, bladder, and kidney cancers, sending Moderna’s stock soaring. This isn’t just a win for melanoma—it’s a blueprint for smarter, more targeted cancer care.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
